Researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). The study, published in Science Translational Medicine and highlighted in Scientific American, found that the blood-brain barrier may remain compromised and permeable for decades following an athlete's retirement from sports involving repetitive head trauma.
When the integrity of the blood-brain barrier becomes compromised, inflammatory molecules and pathogenic toxins in the bloodstream can enter the brain. This neuroinflammation can trigger damaging processes, including the abnormal accumulation of tau protein, a hallmark indicator of CTE. Researchers observed that the former athletes in the study appeared to exist in a persistent state of chronic hyperinflammation.
The Trinity study adds to growing evidence indicating that systemic inflammation is a key driver of neuroinflammation associated with disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. This connection between bloodstream inflammation and brain disorders creates a significant opportunity for blood purification technologies.
Sigyn Therapeutics, developer of CardioDialysis, sees this research as supporting the potential use of their technology to treat neuroinflammatory diseases. CardioDialysis is a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. Given its broad-spectrum mechanism, CardioDialysis is uniquely positioned to emerge as a potential adjunct therapy for neuroinflammatory conditions.
"It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease," stated Sigyn Therapeutics CEO Jim Joyce. "The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain."
Sigyn Therapeutics is pursuing a strategic transaction focused on the use of CardioDialysis to reduce systemic inflammation associated with traumatic brain injury. The company's lead clinical indication for CardioDialysis remains the treatment of cardiovascular disease, the leading cause of death worldwide. However, the technology's underlying mechanism makes it applicable to various conditions involving systemic inflammation.
The implications of this research and technology development are significant for both healthcare and business leaders. For the medical field, it represents a potential paradigm shift in treating neuroinflammatory diseases by addressing systemic inflammation rather than focusing solely on brain-specific interventions. For business and technology leaders, it demonstrates how cross-disciplinary research can create new market opportunities for medical technology companies.
The connection between contact sports, blood-brain barrier disruption, and chronic inflammation highlights a growing public health concern with potential legal and insurance implications for sports organizations. As research continues to establish links between systemic inflammation and neurological disorders, technologies like CardioDialysis could become increasingly valuable in preventive and therapeutic medicine.
